Blau综合征诊疗专家共识（2024版）

doi:10.35541/cjd.20230514

Abstract

Abstract: 【Abstract】 Blau syndrome is a rare autoinflammatory disease caused by monogenic mutations, characterized by a triad of rashes, granulomatous polyarthritis and uveitis. It can affect multiple systems, leading to serious complications that impact patients' quality of life. The Chinese Society of Dermatology and the China Dermatologist Association organized multidisciplinary experts to develop a consensus on the diagnosis and treatment of Blau syndrome based on Chinese and international literature, the current status of its diagnosis and treatment in China and experts' opinions. This consensus focuses on the clinical manifestations, diagnosis, assessment of severity, and treatment of Blau syndrome, aiming to provide a reference for standardized diagnosis and treatment in clinical practice.

Key words: Blau syndrome, Diagnosis, Treatment, Expert consensus

Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on diagnosis and treatment of Blau syndrome （2024）[J]. Chinese Journal of Dermatology, 2024, 57(11): 1004-1010.doi:10.35541/cjd.20230514

References ［49］

［1］	Kaufman KP, Becker ML. Distinguishing Blau syndrome from systemic sarcoidosis［J］. Curr Allergy Asthma Rep, 2021,21（2）:10. doi: 10.1007/s11882⁃021⁃00991⁃3.
［2］	Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis［J］. N Engl J Med, 2007,357（21）:2153⁃2165. doi: 10.1056/NEJMra071714.
［3］	Chiu B, Chan J, Das S, et al. Pediatric sarcoidosis: a review with emphasis on early onset and high⁃risk sarcoidosis and diagnostic challenges［J］. Diagnostics （Basel）, 2019,9（4）:160. doi: 10. 3390/diagnostics9040160.
［4］	Blau EB. Familial granulomatous arthritis, iritis, and rash［J］. J Pediatr, 1985,107（5）:689⁃693. doi: 10.1016/s0022⁃3476（85）80394⁃2.
［5］	张俊梅, 赵晓珍, 唐雪梅, 等. 中国儿童Blau综合征临床特点和治疗分析⁃全国多中心研究［J］. 罕见病研究, 2022,1（3）:252⁃258. doi: 10.12376/j.issn.2097⁃0501.2022.03.005.
［6］	Rosé CD, Pans S, Casteels I, et al. Blau syndrome: cross⁃sectional data from a multicentre study of clinical, radiological and functional outcomes［J］. Rheumatology （Oxford）, 2015,54（6）:1008⁃1016. doi: 10.1093/rheumatology/keu437.
［7］	Miceli⁃Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome［J］. Nat Genet, 2001,29（1）:19⁃20. doi: 10.1038/ng720.
［8］	Wouters CH, Maes A, Foley KP, et al. Blau syndrome, the prototypic auto⁃inflammatory granulomatous disease［J］. Pediatr Rheumatol Online J, 2014,12:33. doi: 10.1186/1546⁃0096⁃12⁃33.
［9］	Kanazawa N, Okafuji I, Kambe N, et al. Early⁃onset sarcoidosis and CARD15 mutations with constitutive nuclear factor⁃kappaB activation: common genetic etiology with Blau syndrome［J］. Blood, 2005,105（3）:1195⁃1197. doi: 10.1182/blood⁃2004⁃07⁃2972.
［10］	Tangye SG, Al⁃Herz W, Bousfiha A, et al. Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee［J］. J Clin Immunol, 2022,42（7）:1473⁃1507. doi: 10.1007/s10875⁃022⁃01289⁃3.
［11］	Aróstegui JI, Arnal C, Merino R, et al. NOD2 gene⁃associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin⁃1 blockade in a Spanish cohort［J］. Arthritis Rheum, 2007,56（11）:3805⁃3813. doi: 10.1002/art.22966.
［12］	Rosé CD, Aróstegui JI, Martin TM, et al. NOD2⁃associated pediatric granulomatous arthritis, an expanding phenotype: study of an international registry and a national cohort in Spain［J］. Arthritis Rheum, 2009,60（6）:1797⁃1803. doi: 10.1002/art. 24533.
［13］	Sarens IL, Casteels I, Anton J, et al. Blau syndrome⁃associated uveitis: preliminary results from an international prospective interventional case series［J］. Am J Ophthalmol, 2018,187:158⁃166. doi: 10.1016/j.ajo.2017.08.017.
［14］	Matsuda T, Kambe N, Ueki Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation［J］. Ann Rheum Dis, 2020,79（11）:1492⁃1499. doi: 10.1136/annrheumdis⁃2020⁃217320.
［15］	Opitz B, Püschel A, Schmeck B, et al. Nucleotide⁃binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae［J］. J Biol Chem, 2004,279（35）:36426⁃36432. doi: 10.1074/jbc.M403861200.
［16］	Theivanthiran B, Batra S, Balamayooran G, et al. NOD2 signaling contributes to host defense in the lungs against Escherichia coli infection［J］. Infect Immun, 2012,80（7）:2558⁃2569. doi: 10.1128/IAI.06230⁃11.
［17］	Arakawa A, Kambe N, Nishikomori R, et al. NOD2 mutation⁃associated case with Blau syndrome triggered by BCG vaccination［J］. Children （Basel）, 2021,8（2）:117. doi: 10.3390/children8020117.
［18］	Poline J, Fogel O, Pajot C, et al. Early⁃onset granulomatous arthritis, uveitis and skin rash: characterization of skin involvement in Blau syndrome［J］. J Eur Acad Dermatol Venereol, 2020,34（2）:340⁃348. doi: 10.1111/jdv.15963.
［19］	Dow CT, Ellingson JL. Detection of Mycobacterium avium ss. Paratuberculosis in Blau syndrome tissues［J］. Autoimmune Dis, 2010,2011:127692. doi: 10.4061/2010/127692.
［20］	Okazaki F, Wakiguchi H, Korenaga Y, et al. A novel mutation in early⁃onset sarcoidosis/Blau syndrome: an association with Propionibacterium acnes［J］. Pediatr Rheumatol Online J, 2021,19（1）:18. doi: 10.1186/s12969⁃021⁃00505⁃5.
［21］	Caso F, Galozzi P, Costa L, et al. Autoinflammatory granulomatous diseases: from Blau syndrome and early⁃onset sarcoidosis to NOD2⁃mediated disease and Crohn's disease［J］. RMD Open, 2015,1（1）:e000097. doi: 10.1136/rmdopen⁃2015⁃000097.
［22］	Saini SK, Rose CD. Liver involvement in familial granulomatous arthritis （Blau syndrome）［J］. J Rheumatol, 1996,23（2）:396⁃399.
［23］	Inoue Y, Kawaguchi Y, Shimojo N, et al. A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early⁃onset sarcoidosis?［J］. Mod Rheumatol, 2013,23（4）:837⁃839. doi: 10.1007/s10165⁃012⁃0720⁃z.
［24］	Yotsumoto S, Takahashi Y, Takei S, et al. Early onset sarcoidosis masquerading as juvenile rheumatoid arthritis［J］. J Am Acad Dermatol, 2000,43（5 Pt 2）:969⁃971. doi: 10.1067/mjd.2000.103754.
［25］	Bittar M, Agarwal S. Sacroiliac involvement in Blau syndrome［J］. Joint Bone Spine, 2021,88（2）:105103. doi: 10.1016/j.jbspin.2020.105103.
［26］	Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis［J］. Autoimmun Rev, 2014,13（12）:1220⁃1229. doi: 10.1016/j.autrev.2014.08.010.
［27］	Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects［J］. Autoimmun Rev, 2012,12（1）:44⁃51. doi: 10.1016/j.autrev.2012.07.028.
［28］	Suresh S, Tsui E. Ocular manifestations of Blau syndrome［J］. Curr Opin Ophthalmol, 2020,31（6）:532⁃537. doi: 10.1097/ICU.0000000000000705.
［29］	郑义, 贾韬, 延聪, 等. 8例Blau综合征/早发型结节病临床表现、病理特征及基因突变的多样性分析［J］. 罕见病研究, 2023,2（2）:170⁃177. doi: 10.12376/j.issn.2097⁃0501.2023.02. 005.
［30］	Li HX, Liu ZM, Zhao SJ, et al. Measuring both procalcitonin and C⁃reactive protein for a diagnosis of sepsis in critically ill patients［J］. J Int Med Res, 2014,42（4）:1050⁃1059. doi: 10.1177/0300060514528483.
［31］	Mizuno K, Nguyen CT, Ueda⁃Hayakawa I, et al. Annular lesions of cutaneous sarcoidosis with granulomatous vasculitis［J］. J Cutan Pathol, 2017,44（5）:494⁃496. doi: 10.1111/cup.12912.
［32］	Thirumal Kumar D, Udhaya Kumar S, Nishaat Laeeque AS, et al. Computational model to analyze and characterize the functional mutations of NOD2 protein causing inflammatory disorder ⁃ Blau syndrome［J］. Adv Protein Chem Struct Biol, 2020,120:379⁃408. doi: 10.1016/bs.apcsb.2019.11.005.
［33］	Li C, Zhang J, Li S, et al. Gene mutations and clinical phenotypes in Chinese children with Blau syndrome［J］. Sci China Life Sci, 2017,60（7）:758⁃762. doi: 10.1007/s11427⁃017⁃9090⁃6.
［34］	Hatemi G, Uçar D, Uygunoğlu U, et al. Behçet syndrome［J］. Rheum Dis Clin North Am, 2023,49（3）:585⁃602. doi: 10.1016/j.rdc.2023.03.010.
［35］	Yao Q, Su LC, Tomecki KJ, et al. Dermatitis as a characteristic phenotype of a new autoinflammatory disease associated with NOD2 mutations［J］. J Am Acad Dermatol, 2013,68（4）:624⁃631. doi: 10.1016/j.jaad.2012.09.025.
［36］	Lassoued Ferjani H, Kharrat L, Ben Nessib D, et al. Management of Blau syndrome: review and proposal of a treatment algorithm［J］. Eur J Pediatr, 2024,183（1）:1⁃7. doi: 10.1007/s00431⁃023⁃05204⁃9.
［37］	Iriqat S, Safieh MA, Fatouleh M, et al. Blau syndrome: a case report from Palestine［J］. Pediatr Rheumatol Online J, 2021,19（1）:138. doi: 10.1186/s12969⁃021⁃00633⁃y.
［38］	Jindal AK, Pilania RK, Suri D, et al. A young female with early onset arthritis, uveitis, hepatic, and renal granulomas: a clinical tryst with Blau syndrome over 20 years and case⁃based review［J］. Rheumatol Int, 2021,41（1）:173⁃181. doi: 10.1007/s00296⁃019⁃04316⁃6.
［39］	PaÇ Kisaarslan A, SÖzerİ B, Şahİn N, et al. Blau syndrome and early⁃onset sarcoidosis: a six case series and review of the literature［J］. Arch Rheumatol, 2020,35（1）:117⁃127. doi: 10.5606/ArchRheumatol.2020.7060.
［40］	Wu S, Zhong L, Sun Z, et al. Ocular features in Chinese patients with Blau syndrome［J］. Ocul Immunol Inflamm, 2020,28（1）:79⁃85. doi: 10.1080/09273948.2019.1569239.
［41］	Wang W, Wang W, Zhong LQ, et al. Thalidomide may be an effective drug for Blau syndrome: a case report［J］. Ann Palliat Med, 2022,11（7）:2538⁃2543. doi: 10.21037/apm⁃21⁃2216.
［42］	Mezouar S, Diarra I, Roudier J, et al. Tumor necrosis factor⁃alpha antagonist interferes with the formation of granulomatous multinucleated giant cells: new insights into Mycobacterium tuberculosis infection［J］. Front Immunol, 2019,10:1947. doi: 10.3389/fimmu.2019.01947.
［43］	Arvesen KB, Herlin T, Larsen DA, et al. Diagnosis and treatment of Blau syndrome/early⁃onset sarcoidosis, an autoinflammatory granulomatous disease, in an infant［J］. Acta Derm Venereol, 2017,97（1）:126⁃127.e7. doi: 10.2340/0001 5555⁃2485.
［44］	Naik AU, Annamalai R, Biswas J. Uveitis in sporadic Blau syndrome: long⁃term follow⁃up of a refractory case treated successfully with adalimumab［J］. Indian J Ophthalmol, 2018,66（10）:1483⁃1485. doi: 10.4103/ijo.IJO_629_18.
［45］	Millington G, Dobson J, Holden S, et al. Sporadic Blau syndrome treated with adalimumab［J］. Clin Exp Dermatol, 2019,44（7）:811⁃813. doi: 10.1111/ced.14016.
［46］	Kitagawa Y, Kawasaki Y, Yamasaki Y, et al. Anti⁃TNF treatment corrects IFN⁃γ⁃dependent proinflammatory signatures in Blau syndrome patient⁃derived macrophages［J］. J Allergy Clin Immunol, 2022,149（1）:176⁃188. doi: 10.1016/j.jaci.2021. 05. 030.
［47］	Lu L, Shen M, Jiang D, et al. Blau syndrome with good reponses to tocilizumab: a case report and focused literature review［J］. Semin Arthritis Rheum, 2018,47（5）:727⁃731. doi: 10.1016/j.semarthrit.2017.09.010.
［48］	Nagakura T, Wakiguchi H, Kubota T, et al. Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome［J］. J Rheumatol, 2017,44（4）:536⁃538. doi: 10.3899/jrheum.160672.
［49］	Zhang S, Cai Z, Mo X, et al. Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients［J］. Pediatr Rheumatol Online J, 2021,19（1）:160. doi: 10.1186/s12969⁃021⁃00634⁃x.

[1]	Lu Qing, Liu Yanqiu, Liu Danping, Zou Yongyi, Yang Bicheng. Variation analysis and prenatal diagnosis in a pedigree with oculocutaneous albinism [J]. Chinese Journal of Dermatology, 2024, 57(9): 842-843.
[2]	Zou Xianbiao, Chen Jinchun, Zeng Yue, Hao Yi. Application of ultrasonography in dermatology: progress and prospects [J]. Chinese Journal of Dermatology, 2024, 57(9): 785-790.
[3]	Zeng Yue, Shao Huihong, Lin Shiwen, Wen Rou, Zou Xianbiao. Application of a wearable teleconsultation device in diagnosis of common skin diseases [J]. Chinese Journal of Dermatology, 2024, 57(9): 797-800.
[4]	He Lan, Ma Ling, Jiang Qian, Chen Liuqing, Chen Hongying. Analysis of dermoscopic and reflectance confocal microscopic characteristics of 57 cases of extragenital lichen sclerosus [J]. Chinese Journal of Dermatology, 2024, 57(9): 791-796.
[5]	Combination of Traditional and Western Medicine Dermatology, Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on the application of reflectance confocal microscopy in common melanocytic skin tumors（2024） [J]. Chinese Journal of Dermatology, 2024, 57(9): 775-784.
[6]	Xia Manqi, Shao Lei, Huang Qiongxiao, Tian Xin, Liang Yimin, Huang Ting, Liang Jingyao, Liu Yumei. Efficacy and safety of dupilumab in the treatment of prurigo nodularis: a multicenter retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 679-684.
[7]	Xie yuanyuan, Liu Yuzhen, Zeng Rong, . Application of skin imaging techniques in acne vulgaris [J]. Chinese Journal of Dermatology, 2024, 57(8): 757-760.
[8]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746.
[9]	Liu Qingfeng, Liu Lian, Diao Ping, Li Xiaoxue, Zhang Ting, Chen Haotian, Liu Xu, Jiang Xian. Diagnosis and treatment of port-wine stains-associated syndromes [J]. Chinese Journal of Dermatology, 2024, 57(7): 656-660.
[10]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[11]	Zhang Ting, Liu Lian, Chen Haotian, Wei Danfeng, Liu Xu, Diao Ping, Liu Qingfeng, Jiang Xian. Efficacy of 595-nm pulsed dye laser in the treatment of port‐wine stains in 155 infants and toddlers: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 610-615.
[12]	The Consensus Development Expert Group of Hematoporphyrin Monomethyl Ether-mediated Photodynamic Therapy for Treating Port-wine Stains. Expert consensus on hematoporphyrin monomethyl ether-mediated photodynamic therapy for treating port-wine stains （2024） [J]. Chinese Journal of Dermatology, 2024, 57(7): 581-589.
[13]	Wang Chen, Xue Chenhong, Song Jinghui, Li Jianguo, Li Zhenlu, Zhang Shoumin, Li Ming, Wang Jianbo. Adalimumab for the treatment of three cases of Blau syndrome in a pedigree [J]. Chinese Journal of Dermatology, 2024, 57(6): 553-556.
[14]	Wang Linxia, Zhang Liming, Shi Meihui, Gao Xinghua, Chen Hongduo, Xiao Ting. Clinical features of 131 patients with chronic spontaneous urticaria accompanied by angioedema or not: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(6): 510-515.
[15]	aser Cosmetology Group, Medical Aesthetics and Cosmetology Branch of Chinese Medical Association, Skin Care Product and Material Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment, Laser Group, Cosmetic and Plastic Surgeon Branch of Chinese Medical Doctor Association, Cosmetic Laser Group, Chinese Society of Dermatology. Guidelines for the diagnosis and treatment of adverse skin reactions to cosmetics （2024 edition） [J]. Chinese Journal of Dermatology, 2024, 57(6): 485-492.

Expert consensus on diagnosis and treatment of Blau syndrome （2024）

PDF

Knowledge

Abstract

Cite this article

share this article

References ［49］

Related Articles 15

Metrics

Comments

Recommended 10